Evercore ISI Group Initiates Coverage On CARISMA Therapeutics with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group has initiated coverage on CARISMA Therapeutics (NASDAQ:CARM) with an Outperform rating and a price target of $12.
July 06, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group's Outperform rating and $12 price target for CARISMA Therapeutics could potentially boost investor confidence and the stock's price in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Evercore ISI Group's positive rating and price target for CARISMA Therapeutics could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100